8-K: Elicio Reports 2025 Results, AMPLIFY-7P Trial Progress

Elicio Therapeutics reported full year 2025 financial results and provided positive updates on its Phase 2 AMPLIFY-7P trial for pancreatic cancer, extending its cash runway into Q3 2026.

Summary

• Elicio Therapeutics reported financial results for the year ended December 31, 2025.
• The event-driven primary disease-free survival (DFS) analysis for the Phase 2 AMPLIFY-7P study evaluating ELI-002 7P in patients with pancreatic ductal adenocarcinoma (PDAC) is anticipated in 1H 2026.
• Fewer disease progressions and deaths than projected to date have been observed in the ongoing 2:1 randomized Phase 2 AMPLIFY-7P trial, though the Company remains blinded to clinical efficacy outcomes.
• The projected cash runway extends into Q3 2026, beyond the anticipated AMPLIFY-7P Phase 2 DFS analysis in 1H 2026.
• In December 2025, evidence of antigen spreading to patient-specific neoantigens beyond mKRAS was reported in the AMPLIFY-7P trial.
• Marc J. Wolfgang was appointed Chief Technology Officer in November 2025.
• Research and development (R&D) expense for 2025 was $24.9 million, a decrease from $33.7 million in 2024.
• General and administrative (G&A) expense for 2025 was $12.8 million, an increase from $11.3 million in 2024.
• Net loss for 2025 was $39.5 million, an improvement from $51.9 million in 2024.
• Net loss per share for 2025 was $2.58, compared to $4.25 for 2024.
• Cash and cash equivalents as of December 31, 2025, were $18.6 million, up from $17.6 million as of December 31, 2024.
• The Company raised approximately $4.9 million in net proceeds in Q4 2025 and $6.3 million in Q1 2026 to date through its at-the-market program.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive update, driven by encouraging early clinical observations in the AMPLIFY-7P trial and an extended cash runway beyond a key data readout, though the company remains pre-revenue with ongoing losses.

Positives

• Fewer disease progressions and deaths than projected have been observed in the Phase 2 AMPLIFY-7P trial to date.
• Evidence of antigen spreading to patient-specific neoantigens was reported, supporting the breadth and potential durability of the ELI-002 7P immune response.
• Cash runway is projected into Q3 2026, extending beyond the anticipated 1H 2026 primary DFS analysis for the AMPLIFY-7P trial.
• Net loss decreased to $39.5 million in 2025 from $51.9 million in 2024.
• R&D expense decreased to $24.9 million in 2025 from $33.7 million in 2024, primarily due to lower clinical costs as patients progressed into the observation phase.
• Appointment of Marc J. Wolfgang as CTO strengthens chemistry, manufacturing, and controls and technical operations capabilities.

Negatives

• General and administrative (G&A) expense increased to $12.8 million in 2025 from $11.3 million in 2024.
• The company continues to operate at a significant net loss of $39.5 million for 2025.
• Reliance on at-the-market (ATM) program for capital raises indicates ongoing need for financing.

Risks

• Ability to obtain the funding necessary to advance the development of ELI-002 7P and any other future product candidates.
• Ability to continue as a going concern.
• The timing and outcome of planned clinical trials, including the event-driven primary DFS endpoint analysis from the Phase 2 AMPLIFY-7P trial, are not guaranteed.
• The potential efficacy of product candidates, including ELI-002 7P, to meaningfully improve outcomes for mKRAS PDAC patients is uncertain.
• The timing of any planned investigational new drug application or new drug application.
• Regulatory alignment for the Phase 3 trial design and initiation of a registrational study is subject to FDA agreement.
• Actual results may differ materially from forward-looking statements due to various factors.

Future Outlook

Elicio anticipates the event-driven primary DFS analysis for the Phase 2 AMPLIFY-7P trial in 1H 2026. Following this, the company plans to request an End-of-Phase 2 meeting with the FDA to finalize the Phase 3 trial design for ELI-002 7P in resected mKRAS PDAC and advance towards a registrational study. Elicio also intends to expand the development of ELI-002 7P to neoadjuvant and metastatic PDAC and other KRAS+ tumors, with continued translational and immunologic data updates expected.

Management Comments

• "In 2025, we made meaningful progress advancing ELI-002 7P in KRAS-mutant pancreatic cancer."
• "We are encouraged by the continued observation of fewer disease progressions and deaths to date than projected in the 2:1 randomized trial, as well as by the durability of T-cell responses and clinical observations reported to date, which reinforce our confidence in ELI-002 7P’s potential to favorably impact outcomes."
• "With capital expected to carry us beyond the anticipated DFS readout, we believe we are well positioned to deliver this important milestone and continue advancing our Amphiphile (AMP) platform in KRAS-mutant PDAC."
• "We remain highly interested in the potential to expand the development of ELI-002 7P to neoadjuvant and metastatic PDAC and other KRAS+ tumors, with the goal of creating meaningful long-term value for patients and shareholders."

Industry Context

StockSavvy.ai notes that Elicio Therapeutics operates in the highly competitive clinical-stage biotechnology sector, specifically focusing on novel immunotherapies for high-prevalence cancers driven by KRAS mutations. Their Amphiphile (AMP) platform aims to deliver immunotherapeutics directly to lymph nodes, a strategy they believe offers superior benefits over conventional approaches. The company's focus on 'off-the-shelf' immunotherapies for mKRAS-positive cancers positions it against both personalized cancer immunotherapies and other targeted therapies, potentially offering advantages in cost, manufacturing, and rapid patient access, particularly in neo-adjuvant settings.

Management Changes

Stakeholder Impact

• Shareholders: Potential for long-term value creation if ELI-002 7P is successful, but also risk of dilution from ongoing capital raises and dependence on future clinical trial outcomes.
• Patients: Potential for a novel, off-the-shelf immunotherapy for mKRAS-positive pancreatic cancer and other solid tumors, offering hope for improved outcomes.
• Employees: Strengthening of the management team with a new CTO, potentially enhancing development and commercialization efforts.
• Creditors/Suppliers: Extended cash runway provides greater certainty for continued operations and ability to meet obligations in the near to medium term.

Next Steps

• Oral presentation in the Targeted Immunotherapies section at the World Vaccine Congress Washington 2026 (March 30-April 2, 2026), scheduled for April 1st at 12:40 PM ET.
• ELI-002 to be highlighted by Dr. Shubham Pant at the American Association for Cancer Research (AACR) Annual Meeting 2026 (April 17-22, 2026), scheduled for April 21st at 12:30 PT.
• Event-driven primary DFS analysis of the Phase 2 AMPLIFY-7P trial anticipated in 1H 2026.
• Plans to request an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) to finalize the Phase 3 trial design for ELI-002 7P following completion of the primary DFS analysis.
• Finalize the Phase 3 protocol and advance ELI-002 7P toward initiation of a registrational study following the primary DFS endpoint analysis, subject to regulatory alignment.
• Continued translational and immunologic data updates from the AMPLIFY 7P program, including additional analyses of antigen spreading and T-cell durability.
• Potential expansion of ELI-002 7P clinical development to neoadjuvant and metastatic PDAC settings, and for other mKRAS-positive cancers.

Key Dates

Recommendation

StockSavvy.ai recommends a 'hold' position. While the early clinical observations for ELI-002 7P are encouraging and the cash runway extends beyond the critical 1H 2026 DFS analysis, the company is still a clinical-stage biotech with significant burn and relies on capital raises. Investors should await the definitive Phase 2 DFS data before making a more aggressive investment decision.

Keywords

Elicio Therapeutics, ELTX, ELI-002 7P, pancreatic cancer, PDAC, KRAS-mutant, immunotherapy, AMP platform, clinical trial, Phase 2, AMPLIFY-7P, DFS, oncology, biotechnology, financial results, antigen spreading